Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
All entries for: Biologic
February 26, 2026
Intellia Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
February 26, 2026
Ionis Pharmaceutical
Neutral Outlook
Carlsbad, CA
1,001-5,000 employees
In addition, the Inflation Reduction Act of 2022, or the IRA, includes key actions aimed at reducing the costs of prescription drugs and allows HHS to negotiate the price of certain single-source drugs covered under Medicare and establish a price cap on such drugs.
Disease Area: Antiviral, Cardiology, Chronic Disease, Hematology, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic
February 26, 2026
Viatris
Layoffs
Canonsburg, PA
10,000+ employees
Viatris is restructuring its global operations and laying off up to 10% of its workforce — potentially up to 3,000 of its 30,000+ employees — over the next three years, targeting R&D, manufacturing, and commercial teams. The company projects savings of $600-700 million from the initiative.
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
February 25, 2026
Innoviva Inc
Negative Outlook
Burlingame, CA
51-200 employees
The cumulative impact of federal and state healthcare reform measures, including the IRA and potential future reforms, may reduce coverage, reimbursement levels, or pricing flexibility for our current or future products.
Disease Area: Infectious Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
February 25, 2026
Arcus Biosciences, Inc.
Neutral Outlook
Hayward, CA
501-1,000 employees
For that and other reasons, it is currently unclear how the IRA will be effectuated, or the impact of the IRA on our business.
Disease Area: Dermatology, Immune Diseases, Oncology
Drug Type: Biologic, Small Molecule
February 25, 2026
Xencor Inc.
Neutral Outlook
Pasadena, CA
201-500 employees
It is unclear how such challenges, and the healthcare reform measures of the current administration, will impact the ACA and our business.
Disease Area: Gastrointestinal, Immune Diseases, Oncology
Drug Type: Biologic